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Function After Weaning From Cardiopulmonary BypassGeir Olav Dahle, MD,*† Pirjo-Riitta Salminen, MD, PhD,*† Christian Arvei Moen, MD, PhD,† Finn Eliassen, CCP,*
Else Nygreen, CCP,* Ville Kytö, MD, PhD,‡§ Pekka Saukko, MD, PhD,¶ Rune Haaverstad, MD, PhD,*†
Knut Matre, MSc, PhD,† and Ketil Grong, MD, PhD†Objectives: To investigate whether adding carvedilol, a
nonselective β- and selective α1-receptor blocking agent
with antioxidant properties, to oxygenated blood cardiople-
gia improves myocardial function after weaning from
bypass.
Design: A randomized controlled study.
Setting: A university laboratory.
Participants: Twenty anesthetized pigs, Norwegian
Landrace.
Interventions: On cardiopulmonary bypass, cardiac arrest
was induced with cold (121C), oxygenated blood cardiople-
gia, enriched with carvedilol or vehicle, and repeated every
20 minutes. After 100 minutes, the heart was reperfused and
weaned.
Measurements and Main Results: Left ventricular function
was evaluated with pressure-volume loops, local myocardial
systolic strain, and strain rate from Speckle tracking analysis
and multilayer short-axis tissue Doppler Imaging. In the
carvedilol group, the load-independent logarithmic end-
diastolic pressure volume relationship, β, decreased from 1
to 3 hours of reperfusion and was low, 0.028  0.004 vand Vascular Anesthesia, Vol 30, No 4 (August)0.042  0.007 (po 0.05) in controls at 3 hours, demonstrat-
ing improved left ventricular compliance. The diastolic
relaxation constant τ was decreased, 28.9  0.6 ms v
34.6  1.3 ms (pgo 0.035), and dP/dtmin was more neg-
ative, 1,462  145 mmHg/s v 1,105  105 mmHg/s (pg ¼
0.024), for carvedilol v control group. The systolic variables,
preload recruitable stroke work and end-systolic pressure-
volume relationship, did not differ between groups, neither
did left ventricular systolic strain and strain rate. Myocardial
oxidative stress, measured as tissue levels of malondialde-
hyde, was reduced by carvedilol, 0.19  0.01 compared to
0.24  0.01 nmol/mg (p ¼ 0.004) in controls.
Conclusions: Carvedilol added to blood cardioplegia
improved diastolic cardiac function and reduced oxidative
stress during the ﬁrst 3 hours after reperfusion in a porcine
model, with 100 minutes of cardioplegic arrest.
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http://dx.doi.org/10.1053/j.jvca.2016.03.152TRANSITORY POSTOPERATIVE left ventricular dys-function, lasting for hours or days, is observed after
cardiopulmonary bypass (CPB) and cardioplegic arrest. This
dysfunction is related to factors like ischemia/reperfusion
injury, apoptosis, adrenergic-receptor desensitization, and
potassium load. Beta-adrenergic receptor blocking agents
reduce both ischemic and reperfusion injury in the myocar-
dium.1-4 Perioperative beta-blockers are also beneﬁcial in
cardiac surgery.5,6 In experimental protocols, both pretreatment
with the short-acting β-blocker esmolol or addition of esmolol
in cold, intermittent, oxygenated blood cardioplegia improves
myocardial contractility in the early hours after CPB and
cardiac arrest.7,8 The occurrence of oxidative stress is a major
component in both lethal reperfusion injury and in recruitment
and activations of neutrophil granulocytes as part of the
inﬂammatory response to CPB.9 Carvedilol, a non-selective
beta- and alpha1-receptor blocker with powerful antioxidative
properties, is therefore of particular interest as a cardioprotec-
tive agent.10 Several studies have shown carvedilol to be superior
to traditional beta-blockers in preserving cardiac function and
reducing ischemic and lethal reperfusion injury in the context of
coronary occlusion and reperfusion.2,3,11 One animal model and
one in vitro study on human atrial myocytes in a perfusion
chamber have demonstrated that carvedilol was acting as an
antiapoptotic agent in the context of cardiopulmonary bypass
and cardioplegic arrest.12,13 In these studies, however, the descrip-
tion of myocardial performance after reperfusion was sparse.
Hyperkalemic, cold, intermittent oxygenated blood cardioplegia
is considered to be the gold standard for myocardial protection
during cardiac surgery.14 When using intermittent oxygenated
blood cardioplegia, cardioplegic arrest is the starting point of ananticipated ischemic period of the myocardium also including
several episodes of reperfusion and reoxygenation. Intracoronary
administration via the cardioplegic solution allows the myocardium
to be exposed to a relatively high concentration of carvedilol during
the extracorporal circulation while avoiding large systemic doses
that may cause severe hemodynamic depression after weaning from
CPB. In this study the authors hypothesized that carvedilol added in
the cardioplegic concentrate would reduce lethal reperfusion injury
and improve cardiac performance during the ﬁrst hours after
weaning from CPB with 100 minutes of cardioplegic arrest by
repeated cold oxygenated blood cardioplegia.
METHODS
Animals and Anesthesia
Twenty-six pigs weighing 43  3 kg (standard deviation)
were used in this study. After at least 7 days of acclimatization, 2016: pp 859–868 859
Fig 1. Schematic timeline for experiments. B, baseline; ACC and
ADC, aortic cross-clamping and declamping; CA, cardioplegic arrest;
HDC and LDC, high- and low-dose cardioplegia; 1h, 2h, and 3h, time
of measurements at one, two, and three hours after aortic
declamping.
Table 1. Calculated Concentrations in Oxygenated Blood
Cardioplegia
High Dose Low Dose
Kþ (mM) 22 14
Mg2þ (mM) 16 9
Cl (mM) 134 120
Procainhydrocloride (mm) 0.8 0.4
DMF (mM) 0.6 0.3
Carvedilol* (mM) 4 2.2
Abbreviation: DMF, dimethylformamide.
*In intervention group only.
DAHLE ET AL860in the animal facility, the pigs were fasted overnight but had
free access to water. All procedures were performed in
accordance with international guidelines described in European
Communities Council Directive of 2010 (63/EU). The exper-
imental protocol was approved by the Norwegian State
Commission for Laboratory Animals (project No. 20113923).
Ketamine (20 mg/kg), diazepam (10 mg), and atropine (1
mg) injected intramuscularly in the dorsal region of the neck
served as premedication. Animals were ventilated with isoﬂur-
ane, 3% in oxygen, for a brief period while 2 ear veins were
cannulated. Intravenous anesthesia then was initiated with
loading doses and continuous infusions with pentobarbital
(15 mg/kg and 4 mg/kg/h), midazolam (0.3 mg/kg and 0.3
mg/kg/h), fentanyl (0.02 mg/kg and 0.02 mg/kg/h) and
vecuronium (0.6 mg/kg and 0.3 mg/kg/h). A tracheotomy
was performed and mechanical ventilation commenced (Julian,
Dräger, Lübeck, Germany) with ﬁxed tidal volumes set at 11
mL/kg. A mixture of 57% N2O and oxygen was used.
Respiratory rate was adjusted to maintain end-tidal CO2
between 5.0 and 5.7 kPa (38 and 43 mmHg). This anesthetic
protocol has been evaluated thoroughly and found to be
hemodynamically stable for at least 7 hours.15,16 At the end
of the experiments, the animals, still under general anesthesia,
were euthanized with saturated potassium chloride injected into
the left atrium.
Surgical Instrumentation
The right femoral artery and vein were cannulated for blood
sampling. A suprapubic catheter was placed into the urinary
bladder and urinary output measured. After a midline sternot-
omy and pericardiotomy, a 6F catheter was placed in the left
atrium for microsphere injections, and sutures for bypass
cannulation were prepared. A loose snare was placed around
the inferior vena cava allowing acute dynamic preload reduc-
tions. A pressure-tip catheter (MPC-500, Millar Corp., Hous-
ton, TX) was placed in the aortic arch via the left internal
thoracic artery. A Swan-Ganz catheter (177HF75-7.5F, Edward
Lifesciences Inc., Irvine, CA) was advanced through the right
ventricle from the left internal thoracic vein to obtain contin-
uous cardiac output, right ventricular end-diastolic volume
(RV-EDV), and right ventricular ejection fraction (RV-EF) as
well as central venous and pulmonary artery pressures. The
catheter was connected to pressure transducers (TruWaves,
Edward Lifesciences) and a continuous cardiac output com-
puter (Vigilance II, Edward Lifesciences). Hemodynamic
measurements were digitized and continuously recorded with
a signal conditioning unit (ACQ-7700, Data Sciences Interna-
tional, St. Paul, MN). Finally a pressure-conductance catheter
(CDLeycom, Hengelo, The Netherlands) was placed throughthe left ventricle from the apex and connected to a signal
conditioner unit (Sigma-M, CDLeycom). Correct placement
was conﬁrmed with echocardiography (Vivid E9, GE Vingmed
Ultrasound, Horten, Norway). After instrumentation, animals
were left to stabilize for 15 minutes before baseline
measurements.Cardiopulmonary Bypass
Cannulation for CPB was done through the brachiocephalic
artery and the right atrial appendage with an 18F arterial
cannula (Medtronic Inc., Minneapolis, MN) and a 29F cav-
oatrial 3-stage cannula (Medtronic Inc.). The priming volume
(1,200 mL Ringer’s acetate) and blood were mixed at full
CPB ﬂow (90 mL/kg/min) for a few minutes before aortic
cross-clamping. A left ventricle venting catheter (E061 17-Fr,
Edwards Lifesciences, Inc.) was introduced via the left atrial
appendage. At a ﬂow rate of 7% of full CPB ﬂow (6.3 mL/kg/
min), hearts were perfused with the “high-dose” oxygenated
cold blood cardioplegia through the aortic root for 3 minutes
(Fig 1, Table 1). After this, new cardioplegic “low-dose”
perfusions were repeated for 2 minutes every 20 minutes.
Active cooling allowed core temperature to drift towards 351C,
and when reached or after 20 minutes of cardioplegic arrest,
CPB ﬂow was reduced to 72 mL/kg/min. After 80 minutes,
rewarming to baseline temperature commenced and CPB ﬂow
was reset to 90 mL/kg/min. Arterial blood gases were drawn
just before, after 50 minutes, and after 98 minutes of aortic
cross-clamping. The aorta was declamped after 100 minutes,
and animals were weaned from CPB and decannulated within
20 minutes. The only antiarrhythmic intervention allowed in
this protocol was electroconversion from ventricular ﬁbrillation
if needed.Design
Animals were block-randomized into a carvedilol group or a
control group. In the carvedilol group, the cardioplegic con-
centrate (1,000 mL) was prepared with 8 mg-carvedilol
dissolved in a vehicle of 250 mL of dimethylformamide and
50 mL of HCl on the day of the experiment. The mixture then
was diluted carefully with the cardioplegic concentrate under
constant stirring to avoid any precipitation. In the control
group, the cardioplegic electrolyte concentrate was prepared in
the same manner but enriched with vehicle only. Evaluation of
cardiac function, tissue blood ﬂow with microspheres, and
blood sampling was performed at baseline and then every hour
CARVEDILOL-ENRICHED BLOOD CARDIOPLEGIA 861after aortic declamping for 3 hours (Fig 1). Tissue samples
were harvested at the end of experiments.
Pressure-Volume Loops
When evaluating cardiac function, 8 to 12 stable heartbeats
were recorded and averaged to evaluate left ventricular
pressures and volumes. Following this, 5 to 10 (mean 7.8)
beats during an acute dynamic preload reduction, obtained by
inferior vena cava constriction, were recorded with the
pressure-conductance catheter to assess load-independent left
ventricular systolic and diastolic variables. Three separate
calibration sequences with 5 mL of 10% saline injected into
the pulmonary artery then were recorded. All measurements
were done during respirator shut-off, and animals were allowed
to stabilize to initial hemodynamic values between recordings.
Unﬁltered data were exported to an in-house-developed soft-
ware coded in Matlab (MathWorks Inc., Natick, MA) for
further analysis. Paradoxical segmental conductance signals,
indicating aortic positioning, were excluded from the total
conductance signal. Parallel conductance was calculated from
the recordings during hypertonic saline injections, whereas
stroke volume from the continuous cardiac output computer
served as alpha correction.17 Left ventricular volumes were
normalized for body surface area.18 The load-independent
measures of contractility, preload recruitable stroke work
(PRSW), and end-systolic pressure-volume relationship
(ESPVR) and diastolic compliance (β), calculated as the
exponential ﬁt of the end-diastolic pressure volume relationship
(EDPVR) (p ¼ C  eβV),19 were based on a minimum of 5
consecutive beats during preload reduction. The median
correlation coefﬁcients (interquartile ranges) were 0.998
(0.999; 0.996) for PRSW, 0.993 (0.997; 0.984) for ESPVR
and 0.992 (0.996; 0.974) for β. The change in heart rate
between the ﬁrst and last cycle was 1.4  3.2 (standard
deviation) beats/min for all 80 runs. The isovolumic relaxation
constant was calculated by the left ventricular pressure wave-
form assuming a non-asymptotic decay.20
Echocardiography
After each microsphere injection and pressure-volume loop
recording, echocardiography was performed with a Vivid E9
scanner (GE Vingmed Ultrasound). A soft silicon pad
(4  4  3 cm) serving as an offset was placed between the
epicardium and the sector probe (6S cardiac probe, GE
Vingmed Ultrasound). The respirator was disconnected during
recordings. Cine-loops of short-axis B-mode view at the
equator were recorded for left ventricular radial and circum-
ferential strain and strain rate using speckle tracking analysis
(STE). With the same probe position recordings of the anterior
wall optimized for multilayer radial tissue Doppler imaging
(TDI) were obtained. The probe then was relocated to the
apical long-axis view for pulsed-wave Doppler velocity record-
ing from the mitral and aortic valves for timing purposes. Still
in long-axis view, 4-chamber B-mode cine-loops of the left
ventricle were obtained for STE analysis. All analyses were
carried out using EchoPac BT12 (GE Vingmed Ultrasound)
with the operator being unaware of the data randomization.
End-diastole was deﬁned as the beginning of the ﬁrst deﬂectionof the QRS complex on electrocardiogram, whereas the end-
systole was deﬁned as the time of aortic valve closure on
corresponding pulsed-wave Doppler spectral recordings. For
TDI analysis, strain length was set to 2 mm, and 3 regions of
interest measuring 2  6 mm were tracked evenly through the
anterior left ventricular wall representing the subendocardial,
midmyocardial, and subepicardial part of the wall.21
Tissue and Blood Samples
Immediately after euthanasia, the heart was removed and
samples from the left ventricle, divided into subendocardial,
midmyocardial, and subepicardial layers, and from the right
ventricle were snap-frozen in liquid nitrogen and stored
at 801C. Corresponding tissue samples were placed in
paraformaldehyde, washed in ethanol, embedded in parafﬁn,
and sectioned for histology. Also, 2 more sets of corresponding
tissue were harvested and weighed for tissue water content and
quantiﬁcation of tissue blood ﬂow rate.
Oxidative stress was studied by lipid peroxidation assessed
by measuring malondialdehyde (MDA) in 10-mg tissue sam-
ples with a ﬂuorometric kit (K739-100, BioVision Inc.,
Milpitas, CA). Likewise, a Caspase-3 Colorimetric Assay kit
(K105-400, BioVision Inc.) was used to quantify caspase-3
activity in tissue samples of 400 mg of total protein as a marker
of initiation of apoptosis. For both kits, triplet samples were
used and tissue was homogenized, lysed, and measured
according to the manufacturer’s instructions.
Cardiomyocyte apoptosis was studied with the terminal
transferase-mediated DNA nick end labeling (TUNEL) assay.22
In brief, parafﬁn-embedded myocardial sections (4 mm) were
heated in a sodium citrate solution and digested with
proteinase-K to expose DNA. Strand breaks of DNA were
then labeled using terminal transferase with digoxigenin con-
jugated dideoxyuridine triphosphate and visualized with alka-
line phosphatase immunohistochemistry. Assay was
standardized using the serial section of each sample treated
with DNaseI as positive control for apoptosis. Percentages of
TUNEL-positive nuclei were calculated using microscopy
(250 magniﬁcation) with an ocular grid.
The myocardial tissue and corresponding reference blood
samples collected for ﬂow rate estimation were weighed,
hydrolyzed, and ﬁltered. Fluorescent dye extracted from micro-
spheres on the ﬁlter was quantiﬁed by ﬂurospectrophotometry
(RF-5301PC, Shimadzu, Kyoto, Japan) and regional tissue
blood ﬂow rate calculated.23 Tissue water content, presented as
fraction of wet-weight, was calculated as the difference
between wet-weight measured immediately after harvest and
after 3 weeks of drying at 601C.
Troponin-T was analyzed according to the hospital clinical
routine (Troponin-T hss, Roche Diagnostics, Mannheim,
Germany). All arterial blood gas samples were analyzed
according to α-stat strategy (Pico 50, Radiometer Medical,
Brønshøj, Denmark).
Statistics
Data were analyzed by using SPSS v23 (SPSS Inc.,
Chicago, IL) and values presented as mean  standard error
of the mean or median (75-percentile; 25-percentile), unless
DAHLE ET AL862otherwise noted. Baseline variables demonstrating normal
distribution were compared by 2-sample Student t-tests. The
2-sample Wilcoxon-Mann-Whitney test on ranks was used if
the Kolmogorov-Smirnov test or the Levene equal variance
tests were signiﬁcant when comparing baseline variables and
tissue Caspase-3 activity in wall layers. Variables obtained
during and after CPB were analyzed separately by 2-way
analyses of variance for repeated measurement (RM-ANOVA)
with time as within factor (pw) and carvedilol or control as
grouping factor (pg) and post hoc Bonferroni contrasts between
individual group means. A similar analysis was used for related
samples in wall layers. If Mauchly’s test of sphericity was
signiﬁcant (po 0.05), the Greenhouse-Geisser adjustment of
degrees of freedom was selected for the evaluation of main
effects. If a signiﬁcant interaction (pio 0.10) effect was found,
new ANOVAs for simple main effects were performed with
adjustment of degrees of freedom. Cell means ﬁnally wereTable 2. Baseline Variables Before Cardioplegic Arrest
Variable Carvedilol (n ¼ 10) Control (n ¼ 10) p*
HR (beats/min) 85  4 79  3 0.24
LV-ESP (mmHg) 104  6 95  4 0.19
LV-ESVi (mL/m
2) 28  2 29  2 0.76
LV-EDP (mmHg) 9.4  0.7 10.3  0.7 0.35
LV-EDVi (mL/m
2) 72 (77; 68) 79 (85; 73) 0.21
SVi (mL/m
2) 44  3 50  2 0.056
CI (L/min/m2) 3.6  0.2 4.0  0.2 0.28
LV-EF (%) 61  3 64  2 0.36
LV-SWi (mmHg mL/m2) 3,917  314 4,184  225 0.50
RV-EDVi (mL/m
2) 140  8 147  7 0.54
RV-EF (%) 25  1 25  1 0.91
STE-CircS (%) 15.8  1.5 18.8  0.6 0.08
STE-LongS (%) 12.1  0.9 13.7  0.9 0.23
STE-RadS (%) 27.2 (48.6; 24.9) 28.2 (36.6; 26.6) 0.85
STE-CircSr (s1) 1.15  0.10 1.22  0.05 0.50
STE-LongSr (s1) 1.05  0.04 1.03  0.03 0.75
STE-RadSr (s1) 2.27  0.23 1.98  0.10 0.25
LV-blood ﬂow
(mL/min/g)†
0.78  0.03 0.75  0.05 0.58
RV-blood ﬂow
(mL/min/g)†
0.56  0.03 0.61  0.05 0.33
MAP (mmHg) 95  5 86  4 0.18
PAP (mmHg) 17.0  1.6 17.1  0.9 0.94
CVP (mmHg) 4.8  0.7 5.5  0.6 0.42
LV-PFR/EDV (s1) 3.9  0.2 4.0  0.3 0.88
SVRi (dyn  s/cm5 m2) 2,025  134 1,646  106 0.040
NOTE. Values are mean  SEM or median (75-percentile; 25-
percentile).
Abbreviations: CI, cardiac index; Circ, circumferential direction;
CVP, mean central venous pressure; EDP, end-diastolic pressure;
EDV, end-diastolic volume; EF, ejection fraction; ESP, end-systolic
pressure; ESV, end-systolic volume; HR, heart rate; i, value indexed
for body surface area; Long, longitudinal direction; LV, left ventricle;
MAP, mean arterial pressure; PAP, mean pulmonary artery pressure;
PFR, peak ﬁlling rate; Rad, radial direction; RV, right ventricle; STE,
left ventricular Speckle Tracking Echocardiography; SV, stroke
volume; SW, stroke work; S, peak systolic strain; Sr, peak systolic
strain rate; SVR, systemic vascular resistance.
*p values from 2-sample t-tests or Mann-Whitney rank sum tests.
†n ¼ 9 in Carvedilol group.compared with Neumann-Keuls multiple contrast tests when
justiﬁed by the preceding ANOVA. A p valueo 0.05 was
considered as statistically signiﬁcant.RESULTS
A total of 6 animals were excluded for non-technical reasons.
In the control group, 3 pigs developed severe pulmonary hyper-
tension and arterial hypoxia shortly after weaning from CPB. In 1
of these animals, a persistent foramen ovale was found. One
animal in the control group developed severe tachyarrhythmia,
making evaluation of cardiac function with pressure-volume loops
meaningless. One animal in the control group did not regain
spontaneous rhythm and could therefore not be weaned from CPB.
One animal in the carvedilol group developed cardiac ﬁbrillation
after weaning and severe cardiac failure after multiple attempts of
electrocardioversion. Excluded animals were replaced in the
subsequent experiment. Results are given for 10 animals in
each group.
Except for a higher systemic vascular resistance (SVRi) in
the carvedilol compared to the control group, there were no
signiﬁcant differences with regard to baseline variables describ-
ing left and right ventricular function, hemodynamics, myo-
cardial blood ﬂow, arterial blood gas analysis, and any other
variable evaluated (Table 2). Mean aortic pressure (MAP)
differed between groups 2 minutes before aortic clamping
(Table 3). All other measurements obtained just before aortic
cross-clamping, during cardioplegic arrest, and just prior to
declamping did not differ. The time from declamping until
spontaneous heart rhythm averaged 189  25 s (n ¼ 20), and
the time to cardiac pulsations averaged 318  31 s with no
signiﬁcant difference between groups.
Heart rate and MAP did not differ between groups after
aortic declamping (pg ¼ 0.22 and pg ¼ 0.18). For both groups,
heart rate increased (pw ¼ 0.001) and MAP decreased
(pwo 0.001) from 30 minutes to 3 hours after declamping
(Fig 2). There was an early increased cardiac index in both
groups from 30 to 40 minutes followed by a slight decrease
over time (pwo 0.047) and with no difference between groups
(pg ¼ 0.28). Parallel to this, stroke volume decreased in both
groups (Table 4). A similar decrease was observed for left
ventricular end-diastolic volume (LV-EDVi), stroke work (LV-
SWi) and RV-EDVi. Mean pulmonary artery pressure, left
ventricular end-systolic pressure (LV-ESP), and SVRi
decreased over time. LV-ESP was elevated in the carvedilol
compared to the control group (pg ¼ 0.023).
A signiﬁcant and gradual decrease was seen in PRSW and
in peak positive of the ﬁrst derivative of left ventricular
pressure (dP/dtmax) during reperfusion in both groups (Fig 3).
Two hours after reperfusion, dP/dtmax was higher in carvedilol-
treated compared to controls, but no signiﬁcant difference was
detectable after 3 hours. Circumferential, longitudinal, and
radial peak systolic STE strain decreased during the three
hours after aortic declamping with no signiﬁcant differences
between groups (Table 4). Peak systolic STE strain rate
remained unaltered. Measured by TDI, the peak systolic radial
strain and strain rate in the left ventricular anterior wall in 3-
wall layers showed the same patterns as STE-derived data
(Supplementary Table 1).
Table 3. Mean Arterial Pressure, Temperature, Hemoglobin, and Arterial Blood Gases During Cardiopulmonary Bypass and Aortic Clamp in Two
Groups of Pigs With 100 Minutes of Cardioplegic Arrest
Variable 2 Min Before X-clamp 50 Min X-clamp 98 Min X-clamp
RM-ANOVA Statistics
pw pg pi
MAP (mmHg)
Carvedilol 56  3* 47  2* 56  4‡ 0.017 0.80 0.041
Control 47  3 51  4 57  5†
Temprect (1C)
Carvedilol 38.7  0.2 34.5  0.1 37.7  0.2 o0.001 0.58 0.61
Control 38.4  0.2 34.5  0.1 37.6  0.2
Hb (g/dL)
Carvedilol 5.7  0.2 6.5  0.2 6.9  0.2 o0.001 0.41 0.46
Control 5.9  0.2 6.9  0.2 7.0  0.2
pH
Carvedilol 7.40  0.01 7.42  0.01 7.47  0.01 o0.001 0.059 0.47
Control 7.38  0.01 7.39  0.01 7.43  0.02
pO2 (kPa)
Carvedilol 16.8  2.0 22.8  2.7 15.9  1.9 0.088 0.28 0.15
Control 18.8  3.0 16.4  1.9 13.9  0.8
pCO2 (kPa)
Carvedilol 5.6  0.2 5.7  0.1 5.0  0.2 o0.001 0.12 0.70
Control 5.8  0.1 6.1  0.2 5.4  0.3
HCO3
 (mmol/L)
Carvedilol 25.5  0.6 27.0  0.6 27.7  0.7 o0.001 0.25 0.35
Control 25.1  0.5 26.2  0.3 26.5  0.3
s-Kþ (mmol/L)
Carvedilol 4.4  0.1 4.8  0.1 5.6  0.2 o0.001 0.23 0.61
Control 4.3  0.1 4.7  0.1 5.4  0.2
s-Naþ (mmol/L)
Carvedilol 141  1 142  1 140  1 0.20 0.45 0.38
Control 140  1 141  1 140  1
NOTE. Values are mean  SEM, n ¼ 10.
Abbreviations: MAP, mean aortic pressure; pg, p value between groups from 2-way RM-ANOVA; pi, p value for interaction from 2-way RM-
ANOVA; pw, p value within-subjects from 2-way RM-ANOVA; RM-ANOVA, analyses of variance for repeated measurement; s, serum levels;
Temprect, rectal temperature.
*Signiﬁcantly different from control at 2 min before X-clamp.
†Signiﬁcantly different from 2 min before X-clamp.
‡Signiﬁcantly different from at 50 min of X-clamp
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gradually decreased (less negative) from 60 to 180 minutes
after declamping in both groups (Fig 3). Furthermore, dP/dtmin
was more negative in carvedilol-treated animals compared to
controls during the observation period. The end-diastolic
compliance, β, decreased signiﬁcantly in the carvedilol group
with a tendency to increase in the control group (pi ¼ 0.028).
At 180 minutes after declamping β was signiﬁcantly decreased
in carvedilol-treated animals compared to controls. In the
carvedilol group the left ventricular isovolumic relaxation
constant, τ, was signiﬁcantly reduced compared to controls
after declamping.
Biopsies from the left ventricle demonstrated a reduction of
tissue MDA in carvedilol-treated animals irrespective of wall
layer (pg ¼ 0.004) (Fig 4). An increased number of TUNEL-
positive nuclei were found in the subendocardium compared to
the midmyocardium and the subepicardium (pw ¼ 0.004) but
with no signiﬁcant difference between treatment groups (pg ¼
0.93). Carvedilol-treated animals displayed much variation in
measurements of tissue caspase-3 activity, resulting in skewed
distribution of data and no statistical differences betweengroups in any wall layer. Troponin-T values in serum did not
differ between groups and averaged 46  5 ng/L at baseline
and 356  24 ng/L 180 minutes after declamping (n ¼ 20).DISCUSSION
In this experimental model, carvedilol, added to repeated,
cold, oxygenated blood, cardioplegia enhanced left ventricular
diastolic function during the ﬁrst 3 hours after declamping
following 100 minutes of cardioplegic arrest. A more negative
dP/dtmin and a shortening of the isovolumic relaxation constant
τ in the carvedilol group compared to the control group
indicated more efﬁcient isovolumic relaxation (Fig 3). Fur-
thermore, the end-diastolic compliance was increased signiﬁ-
cantly in the same group 3 hours after declamping
demonstrated by the reduced slope of the logarithmic EDPVR,
β. There was a signiﬁcant increase in LV-ESP in the carvedilol
group after aortic declamping. Small afterload increases can
shorten τ and accelerate left ventricular pressure decay (dP/
dtmin); a more pronounced afterload increase will have the
opposite effect.24 On the other hand, since β is a load-
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Fig 2. Trend curves for heart rate (HR), mean arterial pressure
(MAP), and cardiac index (CI) from 30 to 180 minutes after aortic
declamping. For CI, n ¼ 9 in the carvedilol group due to technical
failure. Values are mean  SEM. # ¼ statistical signiﬁcant difference
between groups at 170 minutes.
DAHLE ET AL864independent variable describing diastolic compliance, the
improved diastolic function caused by carvedilol is most likely
a result of improved lusitropy.
The improvement in diastolic function could be explained
by increased beta-adrenergic stimulation (ie, by less desensiti-
zation) as adrenergic stimuli via cAMP accelerates the cyto-
solic calcium removal. However, increased adrenergic
stimulation also should be accompanied by a concomitant
increase in systolic variables. This was demonstrated in a
similar model using the ultra-short-acting beta-blocker esmolol
as an additive to the cardioplegic solution.8 In the present
study, no convincing improvement in left ventricular systolic
function was demonstrated (Fig 3). More likely, the antioxidant
properties of carvedilol caused the enhanced diastolic function.
During ischemia, the elevated level of reactive oxygen species
(ROS) is associated with cytosolic calcium overload. In the
present study, the lower MDA levels in the carvedilol group
indicated less oxidative stress over time. Carvedilol is a
scavenger, reducing oxidative stress, and it has been shown
that carvedilol prevents contractures after ischemia in reperfu-
sion models resulting in both better isovolumic relaxation and
end-diastolic compliance.4,11,25In the setting of CPB and cardioplegic arrest, adrenergic
blocking agents may preserve postoperative function by block-
ing the passing catecholamine surge, thus reducing desensiti-
zation of adrenergic receptors. This is likely to be the
mechanism behind the better-preserved contractile function
after CPB demonstrated for esmolol.8 PRSW, dP/dtmax and
echo-derived strain rate increased with esmolol treatment. In
the present study, a signiﬁcant difference between groups for
dP/dtmax 2 hours after declamping was found but no differences
in ESPVR or PRSW. Furthermore, there was no difference
between groups in radial strain rate, also considered to be a
relatively load-independent contractility variable.26 Thus, the
present study did not convincingly demonstrate an effect on
inotropy or on chronotropy by carvedilol. Prevailing adrenergic
receptor blockade by carvedilol after reperfusion may prevent
the adrenergic receptors from responding to endogenous
catecholamines in spite of being more sensitized. On the other
hand, the anticipated systemic plasma concentration of carve-
dilol during and after cardioplegic arrest is low compared to
concentrations shown to have only minimal hemodynamic
suppressive effects.3
Carvedilol prevents beta-adrenergic receptor desensitization
to some extent,27 but in contrast to traditional beta-blockers,
long-term use of carvedilol does not upregulate beta-receptor
densities.28 This has been explained by sophisticated models
demonstrating that carvedilol acts as a biased agonist at an
intracellular level.29,30 The binding of carvedilol to the
adrenergic receptor will not stimulate the G-protein to activate
cAMP signaling via adenylyl cyclase. In contrast to traditional
beta-blockers like esmolol, however, carvedilol will stimulate
G-protein-receptor signaling pathway involving beta-arresting,
which is involved in the decoupling and later internalization of
the adrenergic receptors. Carvedilol may thus be less suited for
protection from the acute beta-adrenergic receptor desensitiza-
tion induced by CPB and cardioplegic arrest.
Alpha1-adrenergic receptors also are known to desensitize early
during acute endogenous surges of cathecholamines. Alpha-andre-
nergic antagonists should therefore have the potential to prevent the
acute decoupling during events like CPB and cardioplegia.31,32 To
the authors’ knowledge, the effect of carvedilol on acute alpha1-
receptor desensitization has not been studied. In the present study,
an increase in LV-ESP in carvedilol-treated animals indicated
elevated afterload (Table 4). Even if systemic concentrations are
low during cardioplegic arrest, carvedilol might alleviate receptor
desensitization by blocking vascular alpha1-adrenergic receptors
during CPB. At baseline there seems to be an elevated afterload in
animals later allocated to carvedilol treatment during cardioplegic
arrest demonstrated by SVRi (Table 2). Both CPB and cardioplegic
arrest have a major cardiovascular impact that would most probably
conceal this randomization bias. Nevertheless, caution should be
taken with regard to interpretation of the afterload difference
demonstrated after CPB in the present study.
Reperfusion is associated with an increase in formation of
ROS due to sudden resupply of oxygen and decay in the
antioxidant system. Also, CPB and cardioplegic arrest promote
neutrophil tissue migration increasing ROS.9 The imbalance
between ROS and antioxidative defense initiates several
reactions, ultimately leading to cell death and is thus a major
mechanism behind reperfusion injury. Carvedilol and its
Table 4. Variables After 100 Minutes of Cardioplegic Arrest and Weaning From Cardiopulmonary Bypass
Variable 1 Hour 2 Hours 3 Hours
RM-ANOVA Statistics
pw pg pi
LV-ESP (mmHg)
Carvedilol 96  6 86  2 79  4 o0.001 0.023 0.96
Control 84  4 73  3 68  4
LV-ESVi (mL/m
2)
Carvedilol 28  4 23  2 20  3 0.18 0.98 0.28
Control 24  4 25  5 22  3
LV-EDP (mmHg)
Carvedilol 7.9  0.7 7.6  0.9 8.2  0.7 0.65 0.47 0.76
Control 7.4  0.8 7.1  0.7 7.2  0.8
LV-EDVi (mL/m
2)
Carvedilol 67  4 56  4 50  4 o0.001 0.78 0.69
Control 65  5 59  6 53  5
SVi (mL/m
2)
Carvedilol 38  1 34  2 30  2 o0.001 0.52 0.36
Control 42  2 34  2 31  2
LV-EF (%)
Carvedilol 59  4 61  2 61  3 0.49 0.59 0.24
Control 66  4 61  4 60  3
LV-SWi (mmHg mL/m2)
Carvedilol 3,241  179 2,682  158 2,121  193 o0.001 0.63 0.51
Control 3,299  255 2,399  247 1,999  199
RV-EDVi (mL/m
2)
Carvedilol 138  7 125  9 122  11 o0.001 0.37 0.26
Control 148  7 141  9 127  8
RV-EF (%)
Carvedilol 30  1 27  1 27  1 0.10 0.64 0.98
Control 29  1 26  2 27  1
LV-blood ﬂow
Carvedilol* 1.22  0.06 0.99  0.07 0.96  0.08 0.005 0.65 0.43
Control 1.10  0.06 0.92  0.12 1.01  0.11
RV-blood ﬂow
Carvedilol* 1.22  0.08 1.13  0.13 1.09  0.11 0.21 0.66 0.51
Control 1.29  0.12 1.09  0.12 1.24  0.12
STE-CircS (%)
Carvedilol 14.7  0.8 15.7  1.5 13.7  1.1 0.03 0.38 0.17
Control 17.8  1.2 15.4  0.8 13.8  0.9
STE-LongS (%)
Carvedilol 10.9  1.1 9.2  0.7 7.7  1.0 0.002 0.98 0.78
Control 10.6  1.1 9.3  0.6 8.1  0.8
STE-RadS (%)
Carvedilol 24.3  2.3 23.0  2.5 20.7  1.4 0.013 0.14 0.37
Control 29.6  2.8 27.2  2.2 20.4  1.7
STE-CircSr (s1)
Carvedilol 1.17  0.07 1.46  0.13 1.37  0.15 0.78 0.31 0.041
Control 1.41  0.11 1.24  0.08 1.26  0.06
STE-LongSr (s1)
Carvedilol 1.07  0.06 1.05  0.08 1.13  0.10 0.76 0.73 0.58
Control 1.10  0.08 1.03  0.04 1.03  0.06
STE-RadSr (s1)
Carvedilol 2.31  0.17 2.21  0.24 2.27  0.23 0.83 0.67 0.97
Control 2.19  0.13 2.15  0.12 2.16  0.19
PAP (mmHg)
Carvedilol 26  2 25  1 22  2 0.008 0.49 0.85
Control 27  1 25  1 24  1
CVP (mmHg)
Carvedilol 6.5  0.8 5.6  0.3 6.0  0.4 0.089 0.80 0.78
Control 6.8  1.0 5.5  0.6 6.6  1.3
LV-PFR/EDV (s1)
Carvedilol 6.0  0.5 6.8  0.9 7.3  0.9 0.056 0.89 0.30
Control 6.5  0.9 6.9  1.0 7.2  0.9
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Table 4 (continued )
Variable 1 Hour 2 Hours 3 Hours
RM-ANOVA Statistics
pw pg pi
SVRi (dyn  s/cm5 m2)
Carvedilol 1,526  125 1,475  98 1,280  104 o0.001 0.092 0.73
Control 1,304  110 1,184  120 1,022  95
NOTE. Variables after 100 min of cardioplegic arrest and weaning from cardiopulmonary bypass. Values are mean  SEM, n ¼ 10 in both
groups.
Abbreviations: Circ, circumferential direction; CVP, mean central venous pressure; EDP, end-diastolic pressure; EDV, end-diastolic volume; EF,
ejection fraction; ESP, end-systolic pressure; ESV, end-systolic volume; i, value indexed for body surface area; Long, longitudinal direction; LV,
left ventricle; PAP, mean pulmonary artery pressure; PFR, peak ﬁlling rate; pg, p value between groups from 2-way RM-ANOVA; pi, p value for
interaction from 2-way RM-ANOVA; pw, p value within subjects from 2-way RM-ANOVA; Rad, radial direction; RM-ANOVA, analyses of variance
for repeated measurement; RV, right ventricle; S, peak systolic strain; Sr, peak systolic strain rate; STE, left ventricular Speckle tracking
echocardiography; SV, stroke volume; SVR, systemic vascular resistance; SW, stroke work.
*n ¼ 9 in Carvedilol group.
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Fig 3. Slope of end-systolic pressure-volume relationship (ESPVR), slope of the logarithmic end-diastolic pressure-volume relationship (β),
slope of preload recruitable stroke work (PRSW), isovolumic relaxation time constant (τ), and peak-positive and peak-negative of ﬁrst derivative
of left ventricular pressure (dP/dtmax and dP/dtmin) at baseline, 1 hour, 2 hours, and 3 hours after aortic declamping. Values are mean  SEM or
median with quartiles. pw, pg, and pi ¼ signiﬁcance level for within, between groups, and interaction, respectively, by analyses of variance for
repeated measurement. # Difference between groups at denoted time. * Difference within same group between 1 and 3 hours.
DAHLE ET AL866
Endo Mid Epi
TU
N
EL
-p
os
tiv
e 
nu
cl
ei
 (%
)
0.02
0.04
0.06
0.08
0.10 p = 0.004
p = 0.93
p = 0.77
Ti
ss
ue
 C
as
pa
se
-3
 a
ct
iv
ity
2
4
6
8
10
12
Endo Mid Epi
Endo Mid Epi
M
D
A
 (n
m
ol
·m
g-
1 )
0.05
0.10
0.15
0.20
0.25
0.30 Carvedilol
Control p = 0.068p = 0.004
= 0.35p
Fig 4. Malondialdehyde (MDA), caspase-3 activity, and TUNEL-
positive nuclei from left ventricular tissue samples in subendocardial
(ENDO), midmyocaridal (MID), and subepicardial (EPI) layers. pw, pg,
and pi ¼ signiﬁcance level for within subjects, between groups, and
interaction, respectively, by RM-ANOVA. Values are mean þ SEM
and box-and-whisker plot for caspase-3.
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idant effects.10 The authors’ study showed less MDA in the
intervention group, indicating reduced lipid peroxidation
(Fig 4). However, neither apoptosis evaluated by caspase-3
activity and TUNEL-staining nor ischemic myocardial injury
evaluated by serum troponin release differed between groups.
In a study using human cardiomyocytes from the right atrium
in a perfusion chamber simulating cardioplegic arrest, signiﬁ-
cantly better preservation with regards to apoptotic activation
was shown when cells were treated with 10 mM of carvedilol.13
Likewise, a systemic injection of 1.0 mg/kg of carvedilol justprior to CPB followed by 1 hour of cardioplegic arrest caused
less apoptotic activation, corresponding to lower MDA levels
in a canine model.12 Furthermore, several studies have shown
marked reduction in infarct size in coronary artery occlusion/
reperfusion models.2-4
The lack of clear evidence for myocardial salvage in the
present study may be dose dependent. Based on plasma volume
of 52 mL/kg in the young pig,33 peak total plasma concen-
trations of carvedilol (free and protein bound) in the
previously-mentioned studies range, between 10 mM and 45
mM. This was signiﬁcantly more than used in the present study,
in which calculated carvedilol concentrations were 5.6 mM and
3.1 mM for high- and low-dose cardioplegia, respectively
(Table 1). However, a direct comparison of systemic bolus
injections and freshly mixed intracoronary delivery probably is
not valid since several factors like distribution volume, blood
temperature and time to equilibrium of plasma protein-bound
fraction will be different. In addition, the repeated perfusions of
intracoronary cardioplegia allow a targeted intervention to the
myocardium during the ischemic and reperfusion periods. In
pilot experiments, double and quadruple doses of carvedilol in
the cardioplegic solution were associated with unacceptable
prolonged asystolic washout periods and problems with wean-
ing from CPB. Thus, the ﬁnal concentrations of carvedilol used
in the present study were titrated to be clinically relevant for the
intracoronary delivery approach.
Limitations
Translating the results from this animal study to a clinical
situation in humans should be done with care. The healthy pig
hearts have not been subjected to a direct surgical intervention.
Many patients undergoing cardiac surgery have a previous
history of ischemic heart disease, myocardial infarction, hyper-
trophy and dysfunction that have not been modeled here.
However, the mechanisms explaining reduced antioxidative
stress combined with improved diastolic function in the present
study were not species speciﬁc. There may very well be similar
advantages utilizing carvedilol-enriched cardioplegia in a
clinical setting, but caution must be taken in choice of dose
as cardiodepression before total washout of cardioplegic
remnants may prolong weaning times. It should also be
emphasized that the statistical power in the present study was
low, and negative ﬁndings must be interpreted with caution.
CONCLUSIONS
In the authors’ pig model, carvedilol used as additive to the
cardioplegic solution reduced oxidative stress in the myocar-
dium. Carvedilol preserves diastolic function during the ﬁrst 3
hours after CPB and cardioplegic arrest. However, the authors
found no evidence of deﬁnitive protection from ischemic and
lethal reperfusion injury.
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